AgingResearch.NewsJoin free
The Lancet Oncology

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

By Toni K. Choueiri, Bernard J. Escudier, Thomas Powles, Show 19 more authorsRobert John Motzer
Randomised trial in 658 peopleInterventions

Registered NCT01865747

Paper

The paper

Toni K. Choueiri, Bernard J. Escudier, Thomas Powles, Show 19 more authorsRobert John Motzer

Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center

The Lancet Oncology, 5 Jun 2016

doi.org/10.1016/s1470-2045(16)30107-3PubMed 27279544

More on Hypertension